CME credits: 0.50

Valid until: 15-04-2025

Claim your CME credit at https://reachmd.com/programs/cme/gprc5d-targeted-bispecifics-in-relapsedrefractory-multiple-myeloma-practical-expert-consensus-on-a-new-target-with-unique-adverse-events/24141/



  
    GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of treatment-emergent adverse events is important to ensure that patients can stay on therapy safely to achieve optimal outcomes. In this educational podcast, myeloma experts weigh in on best-practice management strategies for these toxicities. =

GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-with-immunotherapies/24358/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Managing Immune-Related Adverse Events With Immunotherapies

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Overcoming Barriers to Equitable Care in HNSCC

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-biomarkers-of-response-to-immunotherapeutic-regimens/24356/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens

CME credits: 0.50

Valid until: 03-05-2025

Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/



  
    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events

Download our free app to listen on your phone